6 recruiting, 5 not yet recruiting, 3 completed, 3 withdrawn. 21 Phase 2, 15 Phase 1.
Follow Metastatic Solid Tumors: new trials by email Literature Review of Metastatic Solid Tumors trials Research Report on Metastatic Solid Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IOV-5001 in Adults With Advanced Solid Tumors IOV-5001 - Advanced Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Iovance Biotherapeutics, Inc. | 106 | 2026-09-01 | 2026-09-15 |
| Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors EB-NK-301, Fludarabine - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Beijing Biotech | 60 | 2026-03-02 | 2026-05-15 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-08-03 |
| Image-Guided 125I Seed Implantation Plus Standard Systemic Therapy for Patients With Multiple Metastatic Lesions Standard-of-Care Systemic Therapy, Iodine-125 (125I) Seed Implantation - Metastatic Solid Tumors | Phase 2 | Not yet recruiting | Li Min | 120 | 2026-01-01 | 2026-01-12 |
| Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2) BL-B01D1, VSV injection, CVL006 - Rare Malignant Neoplasm, Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 600 | 2026-01-01 | 2025-12-29 |
| Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors QLC5513 IV infusion, QL1706, IV infusion, platinum, IV infusion - Metastatic Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 290 | 2025-12-30 | 2025-12-09 |
| A Study of BPR-6023021 in Advanced Solid Tumors With Bone Metastases BPR-6023021 for injection - Metastatic Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Chengdu Syncor Pharmaceutical Co., Ltd. | 195 | 2025-11-19 | 2025-11-25 |
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) AVZO-103, Combination Agent - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 355 | 2025-10-02 | 2026-10-05 |
| A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors INCB177054, Retifanlimab - Solid Tumors, Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 9 | 2025-06-30 | 2026-09-02 |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) AVZO-1418, Combination Agent 1, Combination Agent 2 - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 480 | 2025-06-04 | 2026-10-16 |
| A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01) Raludotatug deruxtecan - Advanced Solid Tumor, Metastatic Solid Tumors | Phase 2 | Active not recruiting | Daiichi Sankyo | 335 | 2025-01-06 | 2026-09-24 |
| NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies NP137, anti-PD-1/PD-L1 - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 2 | Active not recruiting | Centre Leon Berard | 57 | 2023-01-06 | 2026-09-25 |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 75 | 2020-03-12 | 2026-09-25 |
| Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Ezabenlimab, BI 754111, BI 836880 - Neoplasm Metastasis, Advanced Tumors | Phase 2 | Completed | Boehringer Ingelheim | 211 | 2019-03-19 | 2026-01-27 |
| ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors ⁸⁹Zr-Df-IAB22M2C - Positron-Emission Tomography, Metastatic Solid Tumors | Phase 2 | Completed | ImaginAb, Inc. | 52 | 2018-12-18 | 2024-07-09 |
| Imaging of Advanced Tumours Using [131]I-IAZA [131]I-IAZA - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Withdrawn | University of Alberta | 2018-12-01 | 2022-07-11 | |
| This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. OBI-888, Globo H IHC Assay - Metastatic Solid Tumors, Locally Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | OBI Pharma, Inc | 54 | 2018-05-07 | 2024-02-22 |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements Oral repotrectinib (TPX-0005) - Locally Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Turning Point Therapeutics, Inc. | 500 | 2017-03-07 | 2026-05-27 |
| Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Mogamulizumab (KW-0761) - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 17 | 2014-10-01 | 2021-04-23 |
| Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies. Cell therapy with bispecific antibodies - Metastatic Solid Tumors | Phase 2 | Withdrawn | Hadassah Medical Organization | 12 | 2002-05-01 | 2011-04-08 |
Showing 20 of 21. Sign in to see all of them.
Neoplasm Metastasis (4) · Carcinoma, Non-Small-Cell Lung (3) · Carcinoma (2) · Colorectal Neoplasms (2) · Lung Neoplasms (2) · Sarcoma (2) · Adenocarcinoma (1) · Biliary Tract Neoplasms (1) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Neuroendocrine (1) · Colonic Diseases (1) · Colonic Neoplasms (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1)
Neoplasms (6) · Digestive System Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Neoplastic Processes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bronchial Neoplasms (3) · Carcinoma, Bronchogenic (3) · Digestive System Neoplasms (3) · Lung Diseases (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3)
repotrectinib (2) · Antibodies, Bispecific (1) · Capsules (1) · Carboplatin (1) · Cell- and Tissue-Based Therapy (1) · Cetuximab (1) · Cisplatin (1) · FANG vaccine (1) · Infusions, Intravenous (1) · Injections (1) · Iodine-125 (1) · Pemetrexed (1) · Platinum (1) · Suspensions (1) · fludarabine (1)
Avenzo Therapeutics, Inc. (2) · Hadassah Medical Organization (2) · Turning Point Therapeutics, Inc. (2) · Beijing Biotech (1) · Boehringer Ingelheim (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Leon Berard (1) · Chengdu Syncor Pharmaceutical Co., Ltd. (1) · Daiichi Sankyo (1) · ImaginAb, Inc. (1) · Incyte Corporation (1) · Iovance Biotherapeutics, Inc. (1) · Li Min (1) · Memorial Sloan Kettering Cancer Center (1) · OBI Pharma, Inc (1)
United States (12) · China (6) · Canada (4) · France (4) · Denmark (3) · Italy (3) · South Korea (3) · Spain (3) · Taiwan (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Israel (2) · Japan (2) · Singapore (2)
Alexander JB McEwan, MB,FRCPC (1) · Apostolia Tsimberidou, MD, PHD (1) · Jedd Wolchok, MD, PhD (1) · Ning Li, MD (1) · Ron Korn, MD, PhD (1) · Shimon Slavin, MD (1) · Wei Fan (1) · Yan Yang (1)
PMID 30093503, PMID 32269053, PMID 34814185, PMID 38197815, PMID 40341199, PMID 41639379
2018 (1), 2023 (1)